Investigation of the protective properties of glycosylphosphatidylinositol-based vaccine candidates in a Toxoplasma gondii mouse challenge model

Glycobiology

Volumn 25, Issue 9, 2015, Pages 984-991

  Götze, Sebastian ^a,b   Reinhardt, Anika ^a,b   Geissner, Andreas ^a,b   Azzouz, Nahid ^a   Tsai, Yu Hsuan ^a,b   Kurucz, Reka ^a,b   Silva, Daniel Varón ^a,b   Seeberger, Peter H ^a,b  

^a MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Carbohydrate microarrays; Glycoimmunology; Glycosylphosphatidylinositol; Toxoplasmosis; Vaccine

Indexed keywords

ANTIBODY; EPITOPE; GLYCOCONJUGATE; GLYCOSYLPHOSPHATIDYLINOSITOL VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL; PROTOZOAL VACCINE; PROTOZOON ANTIBODY;

ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CARBOHYDRATE ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOGENICITY; MICROARRAY ANALYSIS; MOUSE; MOUSE STRAIN; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; FEMALE; IMMUNOLOGY; TOXOPLASMA;

ANIMALS; ANTIBODIES, PROTOZOAN; EPITOPES; FEMALE; GLYCOSYLPHOSPHATIDYLINOSITOLS; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; TOXOPLASMA;

EID: 84943223077     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwv040     Document Type: Article

References (41)

1. Astronomo RD, Burton DR. 2010. Carbohydrate vaccines: Developing sweet solutions to sticky situations? Nat Rev Drug Discov. 9:308-324.
2. Azzouz N, Shams-Eldin H, Niehus S, Debierre-Grockiego F, Bieker U, Schmidt J, Mercier C, Delauw MF, Dubremetz JF, Smith TK, et al. 2006. Toxoplasma gondii grown in human cells uses GalNAc-containing glycosylphosphatidylinositol precursors to anchor surface antigens while the immunogenic Glc-GalNAc-containing precursors remain free at the parasite cell surface. Int J Biochem Cell Biol. 38:1914-1925.
3. Bernatowicz MS, Matsueda GR. 1986. Preparation of peptide-protein immunogens using N-succinimidyl bromoacetate as a heterobifunctional crosslinking reagent. Anal Biochem. 155:95-102.
4. Bröker M, Dull PM, Rappuoli R, Costantino P. 2009. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine. 27:5574-5580.
5. Buskas T, Li Y, Boons G-J. 2004. The immunogenicity of the tumor-associated antigen Lewisy may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chemistry. 10:3517-3524.
6. Debierre-Grockiego F. 2010. Glycolipids are potential targets for protozoan parasite diseases. Trends Parasitol. 26:404-411.
7. Debierre-Grockiego F, Azzouz N, Schmidt J, Dubremetz JF, Geyer H, Geyer R, Weingart R, Schmidt RR, Schwarz RT. 2003. Roles of glycosylphosphatidylinositols of Toxoplasma gondii. Induction of tumor necrosis factor-alpha production in macrophages. J Biol Chem. 278:32987-32993.
8. Debierre-Grockiego F, Campos MA, Azzouz N, Schmidt J, Bieker U, Resende MG, Mansur DS, Weingart R, Schmidt RR, Golenbock DT, et al. 2007. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii. J Immunol. 179:1129-1137.
9. Ferguson MA. 1999. The structure, biosynthesis and functions of glycosylphosphatidylinositol anchors, and the contributions of trypanosome research. J Cell Sci. 112:2799-2809.
10. Fuhrman SA, Joiner KA. 1989. Toxoplasma gondii: Mechanism of resistance to complement-mediated killing. J Immunol. 142:940-947.
11. Geissner A, Anish C, Seeberger PH. 2014. Glycan arrays as tools for infectious disease research. Curr Opin Chem Biol. 18:38-45.
12. Götze S, Azzouz N, Tsai YH, Groß U, Reinhardt A, Anish C, Seeberger PH, Varón Silva D. 2014. Diagnosis of toxoplasmosis using a synthetic glycosylphosphatidylinositol glycan. Angew Chem Int Ed Engl. 53:13701-13705.
13. Guo Z. 2013. Synthetic studies of glycosylphosphatidylinositol (GPI) anchors and GPI-anchored peptides, glycopeptides, and proteins. Curr Org Synth. 10:366-383.
14. Hermanson GT. 2008. Heterobifunctional crosslinkers. In: Hermanson GT, editor. Bioconjugate Techniques. 2nd ed. San Diego (USA): Elsevier. p. 276-335.
15. Hölemann A, Stocker BL, Seeberger PH. 2006. Synthesis of a core arabinomannan oligosaccharide of Mycobacterium tuberculosis. J Org Chem. 71: 8071-8088.
16. Hunter CA, Sibley LD. 2012. Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat Rev Microbiol. 10:766-778.
17. Hunter CA, Suzuki Y, Subauste CS, Remington JS. 1996. Cells and cytokines in resistance to Toxoplasma gondii. In: Gross U, editor. Toxoplasma gondii. Berlin Heidelberg (Germany): Springer-Verlag. p. 113-125.
18. Jacob F, Goldstein DR, Bovin NV, Pochechueva T, Spengler M, Caduff R, Fink D, Vuskovic MI, Huflejt ME, Heinzelmann-Schwarz V. 2012. Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array. Int J Cancer. 130:138-146.
19. Joller N, Weber SS, Müller AJ, Spörri R, Selchow P, Sander P, Hilbi H, Oxenius A. 2010. Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting. Proc Natl Acad Sci USA. 107:20441-20446.
20. Jongert E, Roberts CW, Gargano N, Förster-Waldl E, Petersen E. 2009. Vaccines against Toxoplasma gondii: Challenges and opportunities. Mem Inst Oswaldo Cruz. 104:252-266.
21. Kwon YU, Soucy RL, Snyder DA, Seeberger PH. 2005. Assembly of a series of malarial glycosylphosphatidylinositol anchor oligosaccharides. Chemistry. 11:2493-2504.
22. Luft BJ, Remington JS. 1992. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 15:211-222.
23. Maeda Y, Kinoshita T. 2011. Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins. Prog Lipid Res. 50:411-424.
24. Montoya JG, Liesenfeld O. 2004. Toxoplasmosis. Lancet. 363:1965-1976.
25. Naik RS, Branch OH, Woods AS, Vijaykumar M, Perkins DJ, Nahlen BL, Lal AA, Cotter RJ, Costello CE, Ockenhouse CF, et al. 2000. Glycosylphosphatidylinositol anchors of Plasmodium falciparum: Molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. J Exp Med. 192:1563-1576.
26. Niehus S, Smith TK, Azzouz N, Campos MA, Dubremetz JF, Gazzinelli RT, Schwarz RT, Debierre-Grockiego F. 2014. Virulent and avirulent strains of Toxoplasma gondii which differ in their glycosylphosphatidylinositol content induce similar biological functions in macrophages. PLoS One. 9: e85386.
27. Nikolaev AV, Al-Maharik N. 2011. Synthetic glycosylphosphatidylinositol (GPI) anchors: How these complex molecules have been made. Nat Prod Rep. 28:970-1020.
28. Priest JW, Mehlert A, Moss DM, Arrowood MJ, Ferguson MA. 2006. Characterization of the glycosylphosphatidylinositol anchor of the immunodominant Cryptosporidium parvum 17-kDa antigen. Mol Biochem Parasitol. 149:108-112.
29. Remington JS. 2006. Toxoplasmosis. In: Remington JS, Klein JO, Wilson CB, Baker CJ, editors. Infectious Diseases of the Fetus and Newborn Infant. 6th ed. Philadelphia (USA): Elsevier Saunders. p. 1093-1105.
30. Rudd PM, Morgan BP, Wormald MR, Harvey DJ, van den Berg CW, Davis SJ, Ferguson MA, Dwek RA. 1997. The glycosylation of the complement regulatory protein, human erythrocyte CD59. J Biol Chem. 272:7229-7244.
31. Saksena R, Ma X,Wade TK, Kovác P,Wade WF. 2006. Length of the linker and the interval between immunizations influences the efficacy of Vibrio cholerae O1, Ogawa hexasaccharide neoglycoconjugates. FEMS Immunol Med Microbiol. 47:116-128.
32. Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. 2002. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature. 418:785-789.
33. Sharma SD, Mullenax J, Araujo FG, Erlich HA, Remington JS. 1983. Western Blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol. 131:977-983.
34. Silveira C, Gargano N, Kijlstra A, Petersen E. 2009. Toxoplasma vaccines: appropriate end points and sample size in future human clinical trials. Expert Rev Anti Infect Ther. 7:905-908.
35. Stowell SR, Arthur CM, McBride R, Berger O, Razi N, Heimburg-Molinaro J, Rodrigues LC, Gourdine JP, Noll AJ, von Gunten S, et al. 2014. Microbial glycan microarrays define key features of host-microbial interactions. Nat Chem Biol. 10:470-476.
36. Striepen B, Zinecker CF, Damm JB, Melgers PA, Gerwig GJ, Koolen M, Vliegenthart JF, Dubremetz JF, Schwarz RT. 1997. Molecular structure of the "low molecular weight antigen" of Toxoplasma gondii: A glucose alpha 1-4 N-acetylgalactosamine makes free glycosyl-phosphatidylinositols highly immunogenic. J Mol Biol. 266:797-813.
37. Tsai YH, Götze S, Azzouz N, Hahm HS, Seeberger PH, Varon Silva D. 2011. A general method for synthesis of GPI anchors illustrated by the total synthesis of the low-molecular-weight antigen from Toxoplasma gondii. Angew Chem Int Ed Engl. 50:9961-9964.
38. Tsai YH, Götze S, Vilotijevic I, Grube M, Varón Silva D, Seeberger PH. 2013. A general and convergent synthesis of diverse glycosylphosphatidylinositol glycolipids. Chem Sci. 4:468-481.
39. Tsai YH, Liu X, Seeberger PH. 2012. Chemical biology of glycosylphosphatidylinositol anchors. Angew Chem Int Ed Engl. 51:11438-11456.
40. Wittrock S, Becker T, Kunz H. 2007. Synthetic vaccines of tumor-associated glycopeptide antigens by immune-compatible thioether linkage to bovine serum albumin. Angew Chem Int Ed Engl. 46:5226-5230.
41. Wojcik F, O'Brien AG, Götze S, Seeberger PH, Hartmann L. 2013. Synthesis of carbohydrate-functionalised sequence-defined oligo(amidoamine)s by photochemical thiol-ene coupling in a continuous flow reactor. Chemistry. 19:3090-3098.